Country: Canada
Language: English
Source: Health Canada
NABILONE
RANBAXY PHARMACEUTICALS CANADA INC.
A04AD11
NABILONE
0.25MG
CAPSULE
NABILONE 0.25MG
ORAL
50
Narcotic (CDSA II)
MISCELLANEOUS ANTIEMETICS
Active ingredient group (AIG) number: 0115009003; AHFS:
CANCELLED POST MARKET
2022-10-26
_ _ _ _ _Page 1 of 22_ PRODUCT MONOGRAPH N RAN-NABILONE (nabilone) Capsules; 1mg, 0.5 mg, 0.25 mg Antiemetic Ranbaxy Pharmaceuticals Canada Inc Mississauga, Ontario L5R 3Y4 Date of Preparation: October 18, 2010 Submission Control No: 141934 _ _ _ _ _Page 2 of 22_ NAME OF DRUG N RAN-NABILONE capsules (nabilone) THERAPEUTIC CLASSIFICATION Antiemetic Agent ACTION N RAN-NABILONE (nabilone) is a synthetic cannabinoid with antiemetic properties which have been found to be of value in the management of some patients with nausea and vomiting associated with cancer chemotherapy. It also has sedative and psychotropic effects. After oral administration, comparable peak plasma levels of nabilone and of its carbinol metabolite were attained within 2 hours. The combined plasma concentrations of nabilone and of its carbinol metabolite accounted for, at most, 10 to 20% of the total radiocarbon concentration in plasma. The plasma half-life of nabilone was approximately 2 hours, while that of the total radiocarbon was of the order of 35 hours. Of the two major possible metabolic pathways, stereo-specific enzymatic reduction and direct enzymatic oxidation, the latter appears to be the more important in man. The drug and its metabolites are eliminated mainly in the feces (approximately 65%) and to a lesser extent in the urine (approximately 20%). The major excretory pathway is the bilary system. _ _ _ _ _Page 3 of 22_ INDICATIONS ADULTS: > 18 YEARS N RAN-NABILONE (nabilone) is indicated for the management of severe nausea and vomiting associated with cancer chemotherapy. PEDIATRICS: < 18 YEARS The safety and efficacy of N RAN-NABILONE (nabilone) in the pediatric population have not been established and its use is not recommended in this patient population. GERIATRICS: > 65 YEARS N RAN-NABILONE (nabilone) should be used with caution in the elderly. (See PRECAUTIONS). CONTRAINDICATIONS N RAN-NABILONE (nabilone) is contraindicated in patients with known sensitivity to marijuana or other cannabinoid agents, and in those with a history o Read the complete document